- Center on Health Equity and Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Dr Debra Patt Acknowledges Progress Made Against Cancer
One of the important findings from the American Society of Clinical Oncology’s report is that cancer mortality has gone down, said Debra Patt, MD, MPH, MBA, director of public policy at Texas Oncology.
One of the important findings from the American Society of Clinical Oncology (ASCO)’s report is that cancer mortality has gone down, said Debra Patt, MD, MPH, MBA, director of public policy at Texas Oncology.
Transcript (slightly modified)
What were some of the key findings from ASCO’s annual report on the state of cancer care in the United States?
Well, I think one of the most important things that we recognize today is that while we’re seeing more cancer, cancer mortality continues to go down. So one of the findings in the report was that cancer mortality, in fact, has gone down by 1.5% per year for the last decade. I think that’s representative of progress: progress in screening and early detection, progress in more effective immediate therapies, progress in long-term therapies, and even in patients with incurable illness that they live longer. Those are great successes.
Frameworks for Advancing Health Equity: Urban Health Outreach
May 9th 2024In the series debut episode of "Frameworks for Advancing Health Equity," Mary Sligh, CRNP, and Chelsea Chappars, of Allegheny Health Network, explain how the Urban Health Outreach program aims to improve health equity for individuals experiencing homelessness.
Listen
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Study Highlights Significant Increases in Utilization, Spending on DMD Drugs in Medicaid
May 17th 2024The findings add to recent research on the growing utilization, expenditure, and prices of Duchenne muscular dystrophy (DMD) therapies in the current landscape, an area health care policy could potentially address.
Read More
